Wilmot Research
Wilmot Research
Wilmot is a leader in cancer research and here's why:
- Wilmot Cancer Institute scientists aided in two of the top five cancer discoveries of the past 50 years, as cited by the American Society of Clinical Oncology (ASCO): Contributions to the HPV cervical cancer vaccine, and pioneering work toward anti-nausea therapies to help patients tolerate chemotherapy.
- Wilmot is at the epicenter of cancer control research, as one of two U.S. hubs for the National Community Oncology Research Program (NCORP).
- Wilmot is a trailblazer in aging and cancer research, helping write the evidence-based guidelines​ for managing older patients taking chemotherapy, and starting one of the nation's first geriatric oncology clinics.
- Wilmot is at the forefront of lymphoma research by often leading the nation in clinical trial accruals, holding top positions in key organizations including the SWOG lymphoma committee, and being among the first institutions to offer cellular (CAR T-cell) therapy backed by ongoing research.
Research Programs
Investigators work in three multidisciplinary, collaborative programs that study cancer biology, the tumor microenvironment, and toxicities and side effects of cancer and its treatment.
Research Faculty
Wilmot has more than 125 dedicated scientists from 26 academic departments across the University of Rochester who are devoted to studying cancer.
Shared Resources
Shared Resources provide cost-effective access to state-of-the art technologies, expert guidance and training, and scientific consultation for Wilmot researchers.
Clinical Trials
Clinical trials are the backbone of cancer research, identifying better and safer treatments for patients.
Funding Opportunities
Wilmot offers a variety of intramural funding mechanisms to support cancer researchers, as well as resources for extramural funding.
Membership
A community of scientists investigating how cancer occurs, and better ways to prevent, diagnosis, and treat cancer and its side effects.